- Free from Publisher AAF Sima, M Calvani, M Mehra, A Amato - Diabetes Care, 2005 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—Intention-to-treat patients amounted to 1,257 or
93% of enrolled patients. Efficacy end points were sural nerve morphometry,
nerve conduction velocities, vibration perception thresholds, clinical ... Cited by 52 - Related articles - All 5 versions
D De Grandis, C Minardi - Drugs in R&# 38; D, 2002 - ingentaconnect.com 1 Department of Neuroscience, Ospedale Civile, Rovigo, Italy 2 Neurology Unit,
Bufalini Hospital, Cesena, Italy ... Abstract Objective: To assess the efficacy
and tolerability of acetyl-L-carnitine (levacecarnine; LAC) versus placebo ... Cited by 46 - Related articles - BL Direct - All 3 versions
A Quatraro, P Roca, C Donzella, R Acampora, … - Diabetologia, 1995 - Springer Dear Sir, Diabetic neuropathy is a progressive disorder that causes func- tional
and structural alterations of peripheral nerves. Accord- ing to a recent survey
in a hospital clinic population in the United Kingdom, the overall ... Cited by 33 - Related articles - BL Direct - All 2 versions
E Scarpini, G Sacilotto, P Baron, M Cusini, G … - Journal of the peripheral nervous system: JPNS, 1997 - ncbi.nlm.nih.gov We studied the effects of acetyl-L-carnitine on pain in 16 HIV+ patients
affected by painful distal symmetrical neuropathy. Patients were treated with
0.5-1 gr per day of acetyl-L-carnitine either im or iv for 3 weeks. Pain ... Cited by 41 - Related articles - BL Direct - All 2 versions
- ►diabetesjournals.org L Hays, C Reid, M Doran, K Geary - Diabetes care, 2005 - Am Diabetes Assoc Methadone, a schedule II opioid, was developed in Germany in the 1940s as a
spasmolytic and was not used as an analgesic agent until many years later. In
the 1960s, methadone was researched and tested as a medical treatment for ... Cited by 14 - Related articles - All 6 versions
- ►aspetjournals.org S Chiechio, A Caricasole, E Barletta, M Storto … - Molecular pharmacology, 2002 - ASPET L-Acetylcarnitine (LAC, 100 mg/kg, sc), a drug commonly used for the treatment
of painful neuropathies, substantially reduced mechanical allodynia in rats
subjected to monolateral chronic constriction injury (CCI) of the sciatic ... Cited by 39 - Related articles - BL Direct - All 4 versions
AM Hart, ADH Wilson, C Montovani, C Smith, … - Aids, 2004 - journals.lww.com Background: Nucleoside analogue reverse transcriptase inhibitors (NRTI) disrupt
neuronal mitochondrial DNA synthesis, impairing energy metabolism and resulting
in a distal symmetrical polyneuropathy (DSP), an antiretroviral toxic ... Cited by 46 - Related articles - BL Direct - All 4 versions
A McKay Hart, M Wiberg, G Terenghi - Neuroscience letters, 2002 - Elsevier Peripheral nerve trauma remains a major cause of morbidity, largely due to the
death of 40% of innervating sensory neurons, and to slow regeneration after
repair. Acetyl- -carnitine (ALCAR) is a physiological peptide that ... Cited by 32 - Related articles - All 5 versions
A Maestri, A De Pasquale Ceratti, S Cundari, C … - Tumori, 2005 - tumorionline.it Chemotherapy-induced peripheral neuropathy (CIPN) is often a side effect for
patients with cancer who are treated with neurotoxic chemotherapeutic agents,
and it is defined as inflammation, injury, or de- generation of the ... Cited by 26 - Related articles - View as HTML - All 5 versions
G Bianchi, G Vitali, A Caraceni, S Ravaglia, G … - European Journal of Cancer, 2005 - Elsevier Acetyl-l-carnitine (ALC) improves non-oncological neuropathies. We tested oral
ALC (1 g tid) for 8 weeks in 25 patients with neuropathy grade 3 (common
toxicity criteria – CTC) during paclitaxel or cisplatin therapy, or grade ... Cited by 30 - Related articles - All 15 versions
